Lexeo Therapeutics, Inc. (LXEO)
Nasdaq · Healthcare · Biotechnology
$3.41−3.40%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $280M
- 52-week range
- $2.98 – $10.99
- 52-week change
- −45.44%
- EPS (trailing)
- −$1.02
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Net income
- −$100M
- Diluted EPS
- −$1.86
- Free cash flow
- −$99.0M
From the company’s annual report on SEC EDGAR.
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
Headquarters: New York, United States · 63 employees · lexeotx.com